^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NLRC5 overexpression

    i
    Other names: NLRC5, NLR Family CARD Domain Containing 5, CLR16.1, NOD27, Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat And CARD Domain Containing 5, Nucleotide-Binding Oligomerization Domain Protein 4, Caterpiller Protein 16.1, NOD-Like Receptor C5, Protein NLRC5, NOD4, Nucleotide-Binding Oligomerization Domain Protein 27, Nucleotide-Binding Oligomerization Domains 27
    Entrez ID:
    84166
    Related biomarkers:
    Mutation
    11ms
    NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens. (PubMed, Front Immunol)
    These findings provide a compelling rationale for utilizing NLRC5 overexpression in "cold" tumor models to enhance tumor susceptibility to T-cell recognition and elimination by boosting the presentation of endogenous tumor antigens. This approach holds promise for improving antitumoral immune responses in OC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • NLRC5 (NLR Family CARD Domain Containing 5)
    |
    NLRC5 overexpression
    over1year
    NLRC5 potentiates anti-tumor CD8 T cells responses by activating interferon-β in endometrial cancer. (PubMed, Transl Oncol)
    Taken together, our findings demonstrated that NLRC5 potentiates anti-tumor CD8 T cells responses by activating interferon-β in EC, suggesting that genetically escalated NLRC5 and IFN-β may act as potential candidates for the clinical translation of adjuvant immunotherapies to patients with EC.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • NLRC5 (NLR Family CARD Domain Containing 5) • IFNB1 (Interferon Beta 1)
    |
    NLRC5 overexpression